Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ABL1 | P00519 | 1/20 | 0.31 |
| ▸ | EGFR | P00533 | 1/20 | 0.31 |
| ▸ | HCK | P08631 | 1/20 | 0.31 |
| ▸ | SRC | P12931 | 1/20 | 0.31 |
| ▸ | KDR | P35968 | 1/20 | 0.31 |
| ▸ | PIK3CB | P42338 | 1/20 | 0.31 |
| ▸ | MTOR | P42345 | 1/20 | 0.31 |
| ▸ | PIK3CG | P48736 | 1/20 | 0.31 |
| ▸ | EPHB4 | P54760 | 1/20 | 0.31 |
| ▸ | PRKDC | P78527 | 1/20 | 0.31 |
| ▸ | PI4KB | Q9UBF8 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6738428 | 0.93 | ABL1 (0.32) | ABL1EGFRHCKSRCKDR | |
| SCHEMBL6732649 | 0.76 | ABL1 (0.34) | ABL1EGFRHCKSRCKDR | |
| SCHEMBL6733471 | 0.74 | CRHR1 (0.35) | — | |
| SCHEMBL6736045 | 0.71 | CRHR1 (0.31) | — | |
| SCHEMBL6736701 | 0.66 | CRHR1 (0.34) | — | |
| SCHEMBL7032695 | 0.66 | — | — | |
| SCHEMBL6732927 | 0.66 | CRHR1 (0.31) | — | |
| SCHEMBL6740230 | 0.64 | — | — | |
| SCHEMBL7135375 | 0.64 | CRHR1 (0.34) | — | |
| SCHEMBL6738349 | 0.63 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040023965-A1 | Imidazo-triazines as corticotropin releasing factor antagonists | GILLIGAN PAUL JOSEPH (US) | 2004-02-05 | — | — | US | disclosed |
| US-6579876-B2 | Imidazo(4,5-d)pyridazines | BRISTOL-MYERS SQUIBB PHARMA COMPANY | 2003-06-17 | — | — | US | disclosed |
| US-20030055059-A1 | For therapy of psychiatric disorders and neurological diseases including affective disorder, anxiety, depression, headache, irritable bowel syndrome, post-traumatic stress disorder, supranuclear palsy, immune suppression, Alzheimer's disease | GILLIGAN PAUL JOSEPH (US) | 2003-03-20 | — | — | US | disclosed |
| US-6521636-B1 | Treatment of psychiatric disorders and neurological diseases | BRISTOL-MYERS SQUIBB COMPANY | 2003-02-18 | — | — | US | disclosed |
| US-6365589-B1 | FOR THERAPY OF PSYCHIATRIC DISORDERS AND NEUROLOGICAL DISEASES INCLUDING AFFECTIVE DISORDER, ANXIETY, DEPRESSION, HEADACHE, IRRITABLE BOWEL SYNDROME, POST-TRAUMATIC STRESS DISORDER, SUPRANUCLEAR PALSY, IMMUNE SUPPRESSION, ALZHEIMER'S DISEASE | BRISTOL-MYERS SQUIBB PHARMA COMPANY | 2002-04-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040023965-A1 | Imidazo-triazines as corticotropin releasing factor antagonists | CRH, CRHR1, CRHR2 | ABL1 904/4885EGFR 1255/4885HCK 2027/4885 |
| US-20030055059-A1 | For therapy of psychiatric disorders and neurological diseases including affective disorder, anxiety, depression, headache, irritable bowel syndrome, post-traumatic stress disorder, supranuclear palsy, immune suppression, Alzheimer's disease | CRH, PCNP, CRHR1 | ABL1 4608/4885EGFR 3953/4885HCK 1806/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.